Myriad Genetics Stock Price and Value Analysis

Should you buy Myriad Genetics stock? (NasdaqGS:MYGN). Let's see how it does in our automated value investing analysis system.

  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company pays no dividend.

MYGN Free Cash Flow Trend

Hmm, we can't give any reliable projection for Myriad Genetics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for MYGN
Free Cash Flow trendline for Myriad Genetics

Inside the MYGN Numbers

MYGN Price
(Myriad Genetics stock price per share)
[?] PE Ratio versus Sector 27% lower than other Healthcare stocks
[?] PE Ratio versus Industry 49% lower than other Diagnostics & Research stocks
[?] Cash Yield 0.37%
[?] Free Cash Flow Jitter 53%

Is Myriad Genetics Stock on Sale?

Based on our analysis, we believe that you should not buy Myriad Genetics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy MYGN Stock?

Does Myriad Genetics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.